Researcher’s Profile

Erika Berman Rosenzweig, MD

Medical Director, Pulmonary Hypertension Comprehensive Care Center at Columbia University Medical Center/NewYork-Presbyterian Hospital
Associate Chief, Division of Pediatric Cardiology
Overview: 

Dr. Berman Rosenzweig has extensive experience performing clinical research trials in the field of pulmonary vascular disease, which have been mostly focused on the study of novel medical treatments for pulmonary arterial hypertension and the genomics of pulmonary hypertension.  She has spent the past 15 years collaborating on novel drug trials to improve the options available for patients with pulmonary hypertension and has participated in most of the pivotal clinical trials which prompted FDA approval for these agents. She has also collaborated with genetics teams at CUMC and abroad, who have discovered genetic mutations associated with PAH, and was recently one of six US centers awarded a UO1 grant from NHLBI for the study of PVDOMICS, a collaborative study aimed at defining the future fingerprints of pulmonary vascular disease.

Despite the major advances in medical treatment of PH, there is still no medical cure, and patients often die waiting for lung transplantation given the shortage of suitable donor organs. In response to this need, Dr. Berman Rosenzweig has applied her clinical expertise toward research focused on novel approaches to artificial heart-lung support for pulmonary hypertension.

About: 

Dr. Erika Berman Rosenzweig, Medical Director of the Pulmonary Hypertension Center at Columbia University Medical Center/NewYork-Presbyterian Hospital is considered an international expert in the field of pulmonary hypertension. She has tremendous clinical and research experience in the fields of adult and pediatric pulmonary hypertension. Dr. Rosenzweig is widely published and has devoted remarkable efforts toward clinical research on the study of novel treatments and genetic causes of pulmonary hypertension as well as novel approaches to mechanical support for patients with end-stage pulmonary hypertension. She has been an active member of the PHA and is currently on the Board of Trustees of the Pulmonary Hypertension Association (PHA), Chair of the Scientific Leadership Council of the PHA, immediate past Chair of the Review Committee for PHCC PH Center Accreditation Program, and past Editor-in Chief of the medical journal Advances in Pulmonary Hypertension.